Papakostas GI, Nielsen RZ, Dragheim M, Tonnoir B
Efficacy and tolerability of vortioxetine versus agomelatine, categorized by previous treatment, in patients with major depressive disorder switched after an inadequate response. J Psychiatr Res. 2018 06; 101:72-79.
Efficacy and tolerability of vortioxetine versus agomelatine, categorized by previous treatment, in patients with major depressive disorder switched after an inadequate response.
Petersen T, Papakostas GI, Posternak MA, Kant A, Guyker WM, Iosifescu DV, Yeung AS, Nierenberg AA, Fava M
Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol. 2005 Aug; 25(4):336-41.
Empirical testing of two models for staging antidepressant treatment resistance.
Papakostas GI, Worthington JJ, Iosifescu DV, Kinrys G, Burns AM, Fisher LB, Homberger CH, Mischoulon D, Fava M
The combination of duloxetine and bupropion for treatment-resistant major depressive disorder. Depress Anxiety. 2006; 23(3):178-81.
The combination of duloxetine and bupropion for treatment-resistant major depressive disorder.
Fava M, Graves LM, Benazzi F, Scalia MJ, Iosifescu DV, Alpert JE, Papakostas GI
A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J Clin Psychiatry. 2006 Nov; 67(11):1754-9.
A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment.
Alpert JE, Petersen T, Roffi PA, Papakostas GI, Freed R, Smith MM, Spector AR, Nierenberg AA, Rosenbaum JF, Fava M
Behavioral and emotional disturbances in the offspring of depressed parents with anger attacks. Psychother Psychosom. 2003 Mar-Apr; 72(2):102-6.
Behavioral and emotional disturbances in the offspring of depressed parents with anger attacks.
Papakostas GI, Petersen T, Iosifescu DV, Roffi PA, Alpert JE, Rosenbaum JF, Fava M, Nierenberg AA
Axis III disorders in treatment-resistant major depressive disorder. Psychiatry Res. 2003 May 30; 118(2):183-8.
Axis III disorders in treatment-resistant major depressive disorder.
Yang H, Chuzi S, Sinicropi-Yao L, Johnson D, Chen Y, Clain A, Baer L, McGrath PJ, Stewart JW, Fava M, Papakostas GI
European archives of psychiatry and clinical neuroscience
Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine. Eur Arch Psychiatry Clin Neurosci. 2010 Mar; 260(2):145-50.
Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine.
Fornaro M, Iovieno N, Clementi N, Boscaro M, Paggi F, Balercia G, Fava M, Papakostas GI
The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
Diagnosis of co-morbid axis-I psychiatric disorders among women with newly diagnosed, untreated endocrine disorders. World J Biol Psychiatry. 2010 Dec; 11(8):991-6.
Diagnosis of co-morbid axis-I psychiatric disorders among women with newly diagnosed, untreated endocrine disorders.
Dording CM, Mischoulon D, Goodness TM, Baer L, Clain A, Stewart JW, Matthews JD, McGrath PJ, Nierenberg AA, Fava M, Papakostas GI
Psychoticism and paranoid ideation in patients with nonpsychotic major depressive disorder: prevalence, response to treatment, and impact on short- and long-term treatment outcome. CNS Spectr. 2010 Aug; 15(8):515-21.
Psychoticism and paranoid ideation in patients with nonpsychotic major depressive disorder: prevalence, response to treatment, and impact on short- and long-term treatment outcome.
Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder? J Clin Psychiatry. 2012 May; 73(5):676-83.
Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder?
Canadian journal of psychiatry. Revue canadienne de psychiatrie
Folates and S-adenosylmethionine for major depressive disorder. Can J Psychiatry. 2012 Jul; 57(7):406-13.
Folates and S-adenosylmethionine for major depressive disorder.
Symptoms of fatigue and sleepiness in major depressive disorder. J Clin Psychiatry. 2006; 67 Suppl 6:9-15.
Symptoms of fatigue and sleepiness in major depressive disorder.
Papakostas GI, Trivedi MH, Alpert JE, Seifert CA, Krishen A, Goodale EP, Tucker VL
Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: a meta-analysis of individual patient data from 10 double-blind, randomized clinical trials. J Psychiatr Res. 2008 Jan; 42(2):134-40.
Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: a meta-analysis of individual patient data from 10 double-blind, randomized clinical trials.
Petersen T, Hughes M, Papakostas GI, Kant A, Fava M, Rosenbaum JF, Nierenberg AA
Treatment-resistant depression and Axis II comorbidity. Psychother Psychosom. 2002 Sep-Oct; 71(5):269-74.
Treatment-resistant depression and Axis II comorbidity.
Taneja C, Papakostas GI, Jing Y, Baker RA, Forbes RA, Oster G
Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder. Ann Pharmacother. 2012 May; 46(5):642-9.
Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder.
Papakostas GI, Petersen T, Lebowitz BD, Mischoulon D, Ryan JL, Nierenberg AA, Bottiglieri T, Alpert JE, Rosenbaum JF, Fava M
The international journal of neuropsychopharmacology
The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine. Int J Neuropsychopharmacol. 2005 Dec; 8(4):523-8.
The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine.
Papakostas GI, Nelson JC, Kasper S, Möller HJ
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2008 Feb; 18(2):122-7.
A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder.
Petersen T, Papakostas GI, Bottonari K, Iacoviello B, Alpert JE, Fava M, Nierenberg AA
NEO-FFI factor scores as predictors of clinical response to fluoxetine in depressed outpatients. Psychiatry Res. 2002 Jan 31; 109(1):9-16.
NEO-FFI factor scores as predictors of clinical response to fluoxetine in depressed outpatients.
Papakostas GI, Crawford CM, Scalia MJ, Fava M
Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. A replication of findings with the use of a double-blind, placebo-controlled trial of Hypericum perforatum versus fluoxetine. Neuropsychobiology. 2007; 56(2-3):132-7.
Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. A replication of findings with the use of a double-blind, placebo-controlled trial of Hypericum perforatum versus fluoxetine.
Papakostas GI, Petersen T, Mischoulon D, Green CH, Nierenberg AA, Bottiglieri T, Rosenbaum JF, Alpert JE, Fava M
Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy. J Clin Psychiatry. 2004 Aug; 65(8):1096-8.
Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy.
Papakostas GI, Petersen T, Denninger JW, Tossani E, Pava JA, Alpert JE, Nierenberg AA, Fava M
Psychosocial functioning during the treatment of major depressive disorder with fluoxetine. J Clin Psychopharmacol. 2004 Oct; 24(5):507-11.
Psychosocial functioning during the treatment of major depressive disorder with fluoxetine.
Augmentation of standard antidepressants with atypical antipsychotic agents for treatment-resistant major depressive disorder. Essent Psychopharmacol. 2005; 6(4):209-20.
Augmentation of standard antidepressants with atypical antipsychotic agents for treatment-resistant major depressive disorder.
Journal of psychopharmacology (Oxford, England)
A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. J Psychopharmacol. 2008 Nov; 22(8):843-8.
A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder.
Papakostas GI, Chuzi SE, Sousa JL, Fava M
5HT1A-mediated stimulation of cortisol release in major depression: use of non-invasive cortisol measurements to predict clinical response. Eur Arch Psychiatry Clin Neurosci. 2010 Mar; 260(2):175-80.
5HT1A-mediated stimulation of cortisol release in major depression: use of non-invasive cortisol measurements to predict clinical response.
Freeman MP, Mischoulon D, Tedeschini E, Goodness T, Cohen LS, Fava M, Papakostas GI
Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants. J Clin Psychiatry. 2010 Jun; 71(6):682-8.
Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants.
Surrogate markers of treatment outcome in major depressive disorder. Int J Neuropsychopharmacol. 2012 Jul; 15(6):841-54.
Surrogate markers of treatment outcome in major depressive disorder.
Harley R, Petersen T, Scalia M, Papakostas GI, Farabaugh A, Fava M
Problem-solving ability and comorbid personality disorders in depressed outpatients. Depress Anxiety. 2006; 23(8):496-501.
Problem-solving ability and comorbid personality disorders in depressed outpatients.
Yang H, Sinicropi-Yao L, Chuzi S, Youn SJ, Clain A, Baer L, Chen Y, McGrath PJ, Fava M, Papakostas GI
Residual sleep disturbance and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine. Ann Gen Psychiatry. 2010 Feb 26; 9:10.
Residual sleep disturbance and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine.
Dording CM, Mischoulon D, Shyu I, Alpert JE, Papakostas GI
European psychiatry : the journal of the Association of European Psychiatrists
SAMe and sexual functioning. Eur Psychiatry. 2012 Aug; 27(6):451-4.
Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol. 2009 Jan; 19(1):34-40.
Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.
Diagnostic assessment of major depressive disorder. J Clin Psychiatry. 2009 Apr; 70(4):e09.
Diagnostic assessment of major depressive disorder.
Severe and anxious depression: combining definitions of clinical sub-types to identify patients differentially responsive to selective serotonin reuptake inhibitors. Eur Neuropsychopharmacol. 2012 May; 22(5):347-55.
Severe and anxious depression: combining definitions of clinical sub-types to identify patients differentially responsive to selective serotonin reuptake inhibitors.
Laferton JAC, Vijapura S, Baer L, Clain AJ, Cooper A, Papakostas G, Price LH, Carpenter LL, Tyrka AR, Fava M, Mischoulon D
Mechanisms of Perceived Treatment Assignment and Subsequent Expectancy Effects in a Double Blind Placebo Controlled RCT of Major Depression. Front Psychiatry. 2018; 9:424.
Mechanisms of Perceived Treatment Assignment and Subsequent Expectancy Effects in a Double Blind Placebo Controlled RCT of Major Depression.
Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI
Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020 07; 25(7):1592-1603.
Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).
Papakostas GI, Petersen T, Iosifescu DV, Burns AM, Nierenberg AA, Alpert JE, Rosenbaum JF, Fava M
Obesity among outpatients with major depressive disorder. Int J Neuropsychopharmacol. 2005 Mar; 8(1):59-63.
Obesity among outpatients with major depressive disorder.
Papakostas GI, McGrath P, Stewart J, Charles D, Chen Y, Mischoulon D, Dording C, Fava M
Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder. Psychiatry Res. 2008 Oct 30; 161(1):116-20.
Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder. World J Biol Psychiatry. 2010 Mar; 11(2 Pt 2):300-7.
Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder.
Kinrys G, Gold AK, Pisano VD, Freeman MP, Papakostas GI, Mischoulon D, Nierenberg AA, Fava M
Tachyphylaxis in major depressive disorder: A review of the current state of research. J Affect Disord. 2019 02 15; 245:488-497.
Tachyphylaxis in major depressive disorder: A review of the current state of research.
Papakostas GI, Petersen TJ, Nierenberg AA, Murakami JL, Alpert JE, Rosenbaum JF, Fava M
Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry. 2004 Feb; 65(2):217-21.
Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder.
Petersen T, Papakostas GI, Mahal Y, Guyker WM, Beaumont EC, Alpert JE, Fava M, Nierenberg AA
Psychosocial functioning in patients with treatment resistant depression. Eur Psychiatry. 2004 Jun; 19(4):196-201.
Psychosocial functioning in patients with treatment resistant depression.
Papakostas GI, Miller KK, Petersen T, Sklarsky KG, Hilliker SE, Klibanski A, Fava M
Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. J Clin Psychiatry. 2006 Jun; 67(6):952-7.
Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine.
Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatr Scand. 2008 Apr; 117(4):253-9.
Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder.
Mischoulon D, Papakostas GI, Dording CM, Farabaugh AH, Sonawalla SB, Agoston AM, Smith J, Beaumont EC, Dahan LE, Alpert JE, Nierenberg AA, Fava M
A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder. J Clin Psychiatry. 2009 Dec; 70(12):1636-44.
A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder.
Papakostas GI, Clain A, Ameral VE, Baer L, Brintz C, Smith WT, Londborg PD, Glaudin V, Painter JR, Fava M
International clinical psychopharmacology
Fluoxetine-clonazepam cotherapy for anxious depression: an exploratory, post-hoc analysis of a randomized, double blind study. Int Clin Psychopharmacol. 2010 Jan; 25(1):17-21.
Fluoxetine-clonazepam cotherapy for anxious depression: an exploratory, post-hoc analysis of a randomized, double blind study.
Choi KW, Jang EH, Kim AY, Fava M, Mischoulon D, Papakostas GI, Kim DJ, Kim K, Yu HY, Jeon HJ
Heart rate variability for treatment response between patients with major depressive disorder versus panic disorder: A 12-week follow-up study. J Affect Disord. 2019 03 01; 246:157-165.
Heart rate variability for treatment response between patients with major depressive disorder versus panic disorder: A 12-week follow-up study.
Salloum NC, Fava M, Freeman MP, Flynn M, Hoeppner B, Hock RS, Cusin C, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Papakostas GI
Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. Depress Anxiety. 2019 03; 36(3):235-243.
Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression.
Journal of the history of the neurosciences
Epilepsy and the ancient world: from the magic beliefs of the Babylonians to the Hippocratic scientific thinking. J Hist Neurosci. 1994 Oct; 3(4):233-6.
Epilepsy and the ancient world: from the magic beliefs of the Babylonians to the Hippocratic scientific thinking.
Nierenberg AA, Papakostas GI, Petersen T, Montoya HD, Worthington JJ, Tedlow J, Alpert JE, Fava M
Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. J Clin Psychopharmacol. 2003 Feb; 23(1):92-5.
Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants.
Papakostas GI, Petersen T, Worthington JJ, Roffi PA, Alpert JE, Fava M, Nierenberg AA
A pilot, open study of sertraline in outpatients with treatment-resistant depression (TRD) or with a history of TRD who responded but later relapsed. Int Clin Psychopharmacol. 2003 Sep; 18(5):293-6.
A pilot, open study of sertraline in outpatients with treatment-resistant depression (TRD) or with a history of TRD who responded but later relapsed.
Papakostas GI, Shelton RC, Smith J, Fava M
Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry. 2007 Jun; 68(6):826-31.
Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis.
Freeman MP, Papakostas GI, Hoeppner B, Mazzone E, Judge H, Cusin C, Mathew S, Sanacora G, Iosifescu D, DeBattista C, Trivedi MH, Fava M
Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. J Psychiatr Res. 2019 03; 110:166-171.
Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression.
Papakostas GI, Johe K, Hand H, Drouillard A, Russo P, Kay G, Kashambwa R, Hoeppner B, Flynn M, Yeung A, Martinson MA, Fava M
A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder. Mol Psychiatry. 2020 07; 25(7):1569-1579.
A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder.
Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020 07; 25(7):1604.
Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).
Augmentation strategies in the treatment of major depressive disorder. Examining the evidence on augmentation with atypical antipsychotics. CNS Spectr. 2007 Dec; 12(12 Suppl 22):10-2.
Augmentation strategies in the treatment of major depressive disorder. Examining the evidence on augmentation with atypical antipsychotics.
Major depressive disorder: psychosocial impairment and key considerations in functional improvement. Am J Manag Care. 2009 Dec; 15(11 Suppl):S316-21.
Major depressive disorder: psychosocial impairment and key considerations in functional improvement.
Mischoulon D, Witte J, Levy M, Papakostas GI, Pet LR, Hsieh WH, Pencina MJ, Ward S, Pollack MH, Fava M
Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial. J Clin Psychiatry. 2012 Mar; 73(3):353-7.
Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial.
Chen JA, Papakostas GI, Youn SJ, Baer L, Clain AJ, Fava M, Mischoulon D
Association between patient beliefs regarding assigned treatment and clinical response: reanalysis of data from the Hypericum Depression Trial Study Group. J Clin Psychiatry. 2011 Dec; 72(12):1669-76.
Association between patient beliefs regarding assigned treatment and clinical response: reanalysis of data from the Hypericum Depression Trial Study Group.
Kim K, Shin JH, Myung W, Fava M, Mischoulon D, Papakostas GI, Choi KW, Na EJ, Seo SW, Seong JK, Jeon HJ
Deformities of the Globus Pallidus are Associated with Severity of Suicidal Ideation and Impulsivity in Patients with Major Depressive Disorder. Sci Rep. 2019 05 16; 9(1):7462.
Deformities of the Globus Pallidus are Associated with Severity of Suicidal Ideation and Impulsivity in Patients with Major Depressive Disorder.
Staging Treatment Intensity and Defining Resistant Depression: Historical Overview and Future Directions. J Clin Psychiatry. 2019 06 04; 80(4).
Staging Treatment Intensity and Defining Resistant Depression: Historical Overview and Future Directions.
Associate Professor of Psychology in the Department of Psychiatry
An JH, Jang EH, Kim AY, Fava M, Mischoulon D, Papakostas GI, Na EJ, Jang J, Yu HY, Hong JP, Jeon HJ
Ratio of plasma BDNF to leptin levels are associated with treatment response in major depressive disorder but not in panic disorder: A 12-week follow-up study. J Affect Disord. 2019 12 01; 259:349-354.
Ratio of plasma BDNF to leptin levels are associated with treatment response in major depressive disorder but not in panic disorder: A 12-week follow-up study.
Salloum NC, Fava M, Hock RS, Freeman MP, Flynn M, Hoeppner B, Cusin C, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Papakostas GI
Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. J Affect Disord. 2020 01 01; 260:131-139.
Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression.
Fava M, Dirks B, Freeman MP, Papakostas GI, Shelton RC, Thase ME, Trivedi MH, Liu K, Stankovic S
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY). J Clin Psychiatry. 2019 09 24; 80(6).
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY).
Kim K, Jang EH, Kim AY, Fava M, Mischoulon D, Papakostas GI, Kim H, Na EJ, Yu HY, Jeon HJ
Pre-treatment peripheral biomarkers associated with treatment response in panic symptoms in patients with major depressive disorder and panic disorder: A 12-week follow-up study. Compr Psychiatry. 2019 11; 95:152140.
Pre-treatment peripheral biomarkers associated with treatment response in panic symptoms in patients with major depressive disorder and panic disorder: A 12-week follow-up study.
Salloum NC, Fava M, Ball S, Papakostas GI
Success and efficiency of phase 2/3 adjunctive trials for MDD funded by industry: a systematic review. Mol Psychiatry. 2020 09; 25(9):1967-1974.
Success and efficiency of phase 2/3 adjunctive trials for MDD funded by industry: a systematic review.
Sarris J, Murphy J, Mischoulon D, Papakostas GI, Fava M, Berk M, Ng CH
Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses. Focus (Am Psychiatr Publ). 2018 Jul; 16(3):328-340.
Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses.
Maintaining Rapid Antidepressant Effects Following Ketamine Infusion: A Major Unmet Need. J Clin Psychiatry. 2020 02 04; 81(2).
Maintaining Rapid Antidepressant Effects Following Ketamine Infusion: A Major Unmet Need.
Freeman MP, Hock RS, Papakostas GI, Judge H, Cusin C, Mathew SJ, Sanacora G, Iosifescu DV, DeBattista C, Trivedi MH, Fava M
Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder. J Clin Psychopharmacol. 2020 May/Jun; 40(3):287-292.
Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder.
Fava M, Dirks B, Freeman MP, Shelton RC, Thase ME, Trivedi MH, Papakostas GI, Liu K, Whitworth T, Stankovic S
181 A Phase-2 Sequential Parallel Comparison Design Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder. CNS Spectr. 2020 Apr; 25(2):314-315.
181 A Phase-2 Sequential Parallel Comparison Design Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder.
Freeman MP, Fava M, Dirks B, Jha MK, Shelton RC, Thase ME, Trivedi MH, Papakostas GI, Liu K, Whitworth T, Stankovic S
180 Improvement of Sexual Function Observed During Treatment of Major Depressive Disorder with Adjunctive Pimavanserin. CNS Spectr. 2020 Apr; 25(2):313-314.
180 Improvement of Sexual Function Observed During Treatment of Major Depressive Disorder with Adjunctive Pimavanserin.
Freeman MP, Fava M, Dirks B, Jha MK, Papakostas GI, Shelton RC, Thase ME, Trivedi MH, Liu K, Stankovic S
Improvement of sexual functioning during treatment of MDD with adjunctive pimavanserin: A secondary analysis. Depress Anxiety. 2020 05; 37(5):485-495.
Improvement of sexual functioning during treatment of MDD with adjunctive pimavanserin: A secondary analysis.
Trivedi MH, Papakostas GI, Jackson WC, Rafeyan R
Implementing Measurement-Based Care to Determine and Treat Inadequate Response. J Clin Psychiatry. 2020 05 05; 81(3).
Implementing Measurement-Based Care to Determine and Treat Inadequate Response.
Jackson WC, Papakostas GI, Rafeyan R, Trivedi MH
Recognizing Inadequate Response in Patients With Major Depressive Disorder. J Clin Psychiatry. 2020 05 05; 81(3).
Recognizing Inadequate Response in Patients With Major Depressive Disorder.
Rafeyan R, Papakostas GI, Jackson WC, Trivedi MH
Inadequate Response to Treatment in Major Depressive Disorder: Augmentation and Adjunctive Strategies. J Clin Psychiatry. 2020 05 12; 81(3).
Inadequate Response to Treatment in Major Depressive Disorder: Augmentation and Adjunctive Strategies.
Papakostas GI, Jackson WC, Rafeyan R, Trivedi MH
Inadequate Response to Antidepressant Treatment in Major Depressive Disorder. J Clin Psychiatry. 2020 05 19; 81(3).
Inadequate Response to Antidepressant Treatment in Major Depressive Disorder.
Overcoming Challenges to Treat Inadequate Response in Major Depressive Disorder. J Clin Psychiatry. 2020 05 12; 81(3).
Overcoming Challenges to Treat Inadequate Response in Major Depressive Disorder.
Papakostas GI, Salloum NC, Hock RS, Jha MK, Murrough JW, Mathew SJ, Iosifescu DV, Fava M
Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis. J Clin Psychiatry. 2020 05 26; 81(4).
Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis.
Dichtel LE, Carpenter LL, Nyer M, Mischoulon D, Kimball A, Deckersbach T, Dougherty DD, Schoenfeld DA, Fisher L, Cusin C, Dording C, Trinh NH, Pedrelli P, Yeung A, Farabaugh A, Papakostas GI, Chang T, Shapero BG, Chen J, Cassano P, Hahn EM, Rao EM, Brady RO, Singh RJ, Tyrka AR, Price LH, Fava M, Miller KK
Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week Randomized Placebo-Controlled Study. Am J Psychiatry. 2020 10 01; 177(10):965-973.
Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week Randomized Placebo-Controlled Study.
Johe KK, Kay G, Kumar S, Burdick KE, McIntyre RS, Papakostas GI, Fava M
Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists
NSI-189 phosphate, a novel neurogenic compound, selectively benefits moderately depressed patients: A post-hoc analysis of a phase 2 study of major depressive disorder. Ann Clin Psychiatry. 2020 08; 32(3):182-196.
NSI-189 phosphate, a novel neurogenic compound, selectively benefits moderately depressed patients: A post-hoc analysis of a phase 2 study of major depressive disorder.
Papakostas GI, Fava M, Freeman MP, Shelton RC, Thase ME, Jha MK, Trivedi MH, Dirks B, Liu K, Stankovic S
Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study. Int Clin Psychopharmacol. 2020 11; 35(6):313-321.
Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study.
Shelton RC, Fava M, Freeman MP, Thase ME, Papakostas GI, Jha MK, Trivedi MH, Dirks B, Liu K, Stankovic S
Effect of adjunctive pimavanserin on suicidal ideation in patients with major depression: Analysis of the CLARITY study. J Affect Disord. 2020 12 01; 277:478-485.
Effect of adjunctive pimavanserin on suicidal ideation in patients with major depression: Analysis of the CLARITY study.
Fava M, Mazzone E, Freeman M, Flynn M, Judge H, Hoeppner B, Hock RS, Shui A, Macaluso M, Morrison MF, Carpenter LL, Shelton R, Zajecka J, Papakostas GI
Double-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depression. Ann Clin Psychiatry. 2020 02; 32(4):18-26.
Double-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depression.
Happiness and Treatment Outcome in Resistant Depression. J Clin Psychiatry. 2020 11 10; 81(6).
Happiness and Treatment Outcome in Resistant Depression.
Jha MK, Fava M, Freeman MP, Thase ME, Papakostas GI, Shelton RC, Trivedi MH, Dirks B, Liu K, Stankovic S
Effect of Adjunctive Pimavanserin on Sleep/Wakefulness in Patients With Major Depressive Disorder: Secondary Analysis From CLARITY. J Clin Psychiatry. 2020 12 01; 82(1).
Effect of Adjunctive Pimavanserin on Sleep/Wakefulness in Patients With Major Depressive Disorder: Secondary Analysis From CLARITY.
Choi KW, Jang EH, Kim AY, Kim H, Park MJ, Byun S, Fava M, Mischoulon D, Papakostas GI, Yu HY, Jeon HJ
Predictive inflammatory biomarkers for change in suicidal ideation in major depressive disorder and panic disorder: A 12-week follow-up study. J Psychiatr Res. 2021 01; 133:73-81.
Predictive inflammatory biomarkers for change in suicidal ideation in major depressive disorder and panic disorder: A 12-week follow-up study.
Impact of Supplementation and Nutritional Interventions on Pathogenic Processes of Mood Disorders: A Review of the Evidence. Nutrients. 2021 Feb 26; 13(3).
Impact of Supplementation and Nutritional Interventions on Pathogenic Processes of Mood Disorders: A Review of the Evidence.
McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, Brietzke E, Dodd S, Gorwood P, Ho R, Iosifescu DV, Lopez Jaramillo C, Kasper S, Kratiuk K, Lee JG, Lee Y, Lui LMW, Mansur RB, Papakostas GI, Subramaniapillai M, Thase M, Vieta E, Young AH, Zarate CA, Stahl S
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. Am J Psychiatry. 2021 05 01; 178(5):383-399.
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
Feeney A, Hock RS, Freeman MP, Flynn M, Hoeppner B, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Fava M, Papakostas GI
The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study. Eur Neuropsychopharmacol. 2021 08; 49:122-132.
The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study.
Iovieno N, Papakostas GI, Feeney A, Fava M, Mathew SJ, Iosifescu DI, Murrough JW, Macaluso M, Hock RS, Jha MK
Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset. J Clin Psychiatry. 2021 06 15; 82(4).
Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset.
Feeney A, Hock RS, Fava M, Hernández Ortiz JM, Iovieno N, Papakostas GI
Antidepressants in children and adolescents with major depressive disorder and the influence of placebo response: A meta-analysis. J Affect Disord. 2022 05 15; 305:55-64.
Antidepressants in children and adolescents with major depressive disorder and the influence of placebo response: A meta-analysis.
Price RB, Kissel N, Baumeister A, Rohac R, Woody ML, Ballard ED, Zarate CA, Deakin W, Abdallah CG, Feder A, Charney DS, Grunebaum MF, Mann JJ, Mathew SJ, Gallagher B, McLoughlin DM, Murrough JW, Muthukumaraswamy S, McMillan R, Sumner R, Papakostas G, Fava M, Hock R, Phillips JL, Blier P, Shiroma P, Šóš P, Su TP, Chen MH, Tiger M, Lundberg J, Wilkinson ST, Wallace ML
International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators. Mol Psychiatry. 2022 12; 27(12):5096-5112.
International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators.
Rhee TG, Shim SR, Forester BP, Nierenberg AA, McIntyre RS, Papakostas GI, Krystal JH, Sanacora G, Wilkinson ST
Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2022 12 01; 79(12):1162-1172.
Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode: A Systematic Review and Meta-analysis.
Feeney A, Hoeppner BB, Freeman MP, Flynn M, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, DeBattista C, Ionescu DF, Cusin C, Papakostas GI, Jha MK, Fava M
Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study. J Clin Psychiatry. 2022 11 14; 84(1).
Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study.
Hock RS, Feeney A, Iovieno N, Murrough JW, Mathew SJ, Iosifescu DV, Fava M, Jha MK, Papakostas GI
Rapidity of Symptom Improvement With Intranasal Esketamine for Major Depressive Disorder: A Systematic Review and Meta-Analysis. J Clin Psychiatry. 2022 12 12; 84(1).
Rapidity of Symptom Improvement With Intranasal Esketamine for Major Depressive Disorder: A Systematic Review and Meta-Analysis.
The Psychiatric clinics of North America
Pharmacotherapy: Ketamine and Esketamine. Psychiatr Clin North Am. 2023 06; 46(2):277-290.
Pharmacotherapy: Ketamine and Esketamine.
Papakostas GI, Trivedi MH, Shelton RC, Iosifescu DV, Thase ME, Jha MK, Mathew SJ, DeBattista C, Dokucu ME, Brawman-Mintzer O, Currier GW, McCall WV, Modirrousta M, Macaluso M, Bystritsky A, Rodriguez FV, Nelson EB, Yeung AS, Feeney A, MacGregor LC, Carmody T, Fava M
Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial. Mol Psychiatry. 2024 Aug; 29(8):2287-2295.
Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial.
Guidetti C, Feeney A, Hock RS, Iovieno N, Hernández Ortiz JM, Fava M, Papakostas GI
Antidepressants in the acute treatment of post-traumatic stress disorder in adults: a systematic review and meta-analysis. Int Clin Psychopharmacol. 2025 May 01; 40(3):138-147.
Antidepressants in the acute treatment of post-traumatic stress disorder in adults: a systematic review and meta-analysis.
Thase ME, Montgomery S, Papakostas GI, Bauer M, Trivedi MH, Svedsäter H, Locklear JC, Gustafsson U, Datto C, Eriksson H
Quetiapine XR monotherapy in major depressive disorder: a pooled analysis to assess the influence of baseline severity on efficacy. Int Clin Psychopharmacol. 2013 May; 28(3):113-20.
Quetiapine XR monotherapy in major depressive disorder: a pooled analysis to assess the influence of baseline severity on efficacy.
Nyer M, Farabaugh A, Fehling K, Soskin D, Holt D, Papakostas GI, Pedrelli P, Fava M, Pisoni A, Vitolo O, Mischoulon D
Relationship between sleep disturbance and depression, anxiety, and functioning in college students. Depress Anxiety. 2013 Sep; 30(9):873-80.
Relationship between sleep disturbance and depression, anxiety, and functioning in college students.
Papakostas GI, Culpepper L, Fayyad RS, Musgnung J, Guico-Pabia CJ
Efficacy of desvenlafaxine 50 mg compared with placebo in patients with moderate or severe major depressive disorder: a pooled analysis of six randomized, double-blind, placebo-controlled studies. Int Clin Psychopharmacol. 2013 Nov; 28(6):312-21.
Efficacy of desvenlafaxine 50 mg compared with placebo in patients with moderate or severe major depressive disorder: a pooled analysis of six randomized, double-blind, placebo-controlled studies.
Bauer M, Demyttenaere K, El-Khalili N, Thase ME, Papakostas GI, Szamosi J, Earley WR, Eriksson H
Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment. Int Clin Psychopharmacol. 2014 Jan; 29(1):16-25.
Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment.
Resolution of sleepiness and fatigue: a comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union. J Psychopharmacol. 2014 Feb; 28(2):118-24.
Resolution of sleepiness and fatigue: a comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union.
Iovieno N, Tedeschini E, Levkovitz Y, Ameral VE, Papakostas GI
Does the frequency of follow-up assessments affect clinical trial outcome? A meta-analysis and meta-regression of placebo-controlled randomized trials. Int J Neuropsychopharmacol. 2012 Apr; 15(3):289-96.
Does the frequency of follow-up assessments affect clinical trial outcome? A meta-analysis and meta-regression of placebo-controlled randomized trials.
Cognitive symptoms in patients with major depressive disorder and their implications for clinical practice. J Clin Psychiatry. 2014 Jan; 75(1):8-14.
Cognitive symptoms in patients with major depressive disorder and their implications for clinical practice.
Mischoulon D, Price LH, Carpenter LL, Tyrka AR, Papakostas GI, Baer L, Dording CM, Clain AJ, Durham K, Walker R, Ludington E, Fava M
A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder. J Clin Psychiatry. 2014 Apr; 75(4):370-6.
A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder.
Sarris J, Papakostas GI, Vitolo O, Fava M, Mischoulon D
S-adenosyl methionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. J Affect Disord. 2014 Aug; 164:76-81.
S-adenosyl methionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response.
Guidetti C, Papakostas GI, Pani L, De Martin S, Serra G, Apicella M, Kröger C, Champasa P, Comai S, Mattarei A, Folli F, Pappagallo M, Manfredi PL, Fava M
Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Antidepressant Tachyphylaxis: An Exploratory Post Hoc Analysis From a Phase 3 Randomized Controlled Trial. J Clin Psychiatry. 2025 Oct 06; 86(4).
Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Antidepressant Tachyphylaxis: An Exploratory Post Hoc Analysis From a Phase 3 Randomized Controlled Trial.
Chaikali S, Guidetti C, Trivedi MH, Shelton RC, Iosifescu DV, Thase ME, Jha MK, Mathew SJ, DeBattista C, Dokucu ME, Brawman-Mintzer O, Currier GW, McCall WV, Macaluso M, Bystritsky A, Rodriguez FV, Nelson EB, Yeung AS, MacGregor LC, Carmody T, Fava M, Papakostas GI
Patient treatment preference as a predictor of clinical outcomes in subjects with treatment-resistant depression: a comparative effectiveness research trial for antidepressant incomplete and nonresponders with treatment-resistant depression (ASCERTAIN-TRD). Int Clin Psychopharmacol. 2026 May 01; 41(3):184-191.
Patient treatment preference as a predictor of clinical outcomes in subjects with treatment-resistant depression: a comparative effectiveness research trial for antidepressant incomplete and nonresponders with treatment-resistant depression (ASCERTAIN-TRD).
Guidetti C, Chaikali S, Trivedi MH, Shelton RC, Iosifescu DV, Thase ME, Jha MK, Mathew SH, DeBattista C, Dokucu ME, Brawman-Mintzer O, Hernández Ortiz JM, Currier GW, McCall WV, Modirrousta M, Macaluso M, Bystritsky A, Vila-Rodriguez F, Nelson EB, Yeung AS, MacGregor LC, Carmody T, Fava M, Papakostas GI
Comparative Effectiveness Research Trial for Antidepressant Incomplete and Nonresponders With Treatment Resistant Depression (ASCERTAIN-TRD): Effect of Aripiprazole or Repetitive Transcranial Magnetic Stimulation Augmentation Versus Switching to the Antidepressant Venlafaxine on Quality of Life. J Clin Psychiatry. 2025 Aug 11; 86(3).
Comparative Effectiveness Research Trial for Antidepressant Incomplete and Nonresponders With Treatment Resistant Depression (ASCERTAIN-TRD): Effect of Aripiprazole or Repetitive Transcranial Magnetic Stimulation Augmentation Versus Switching to the Antidepressant Venlafaxine on Quality of Life.
Kapadia S, Zhang Z, Ardic F, Patel M, Thase ME, Papakostas GI
Adjunctive brexpiprazole in patients with major depressive disorder who show minimal or partial response to antidepressant treatment: post hoc analysis of randomized controlled trials. Int J Neuropsychopharmacol. 2025 Oct 01; 28(10).
Adjunctive brexpiprazole in patients with major depressive disorder who show minimal or partial response to antidepressant treatment: post hoc analysis of randomized controlled trials.
Goldberg JF, McIntyre RS, Swartz HA, Freeman MP, Mago R, Citrome L, Rosenblat JD, Thase ME, Tohen M, Vieta E, Malhi GS, Sajatovic M, Shelton RC, Macaluso M, Berk M, Perlis RH, Ostacher MJ, Khan A, Iosifescu DV, Sanacora G, Rubio JM, Kane JM, Goodman DW, Nierenberg AA, Correll CU, Kupka R, Kasper S, Furukawa TA, Davis L, Aaronson ST, Gitlin MJ, Jha MK, Cohen LJ, Papakostas GI, Mitchell PB, Gorwood P, Gupta S, Frye MA, Young AH, Zohar J, Steingard S, Zarate CA, Clayton AH
Recommendations for the Deprescribing of Psychotropic Medications: A Consensus Statement From the American Society of Clinical Psychopharmacology Task Force. JAMA Netw Open. 2026 Feb 02; 9(2):e260043.
Recommendations for the Deprescribing of Psychotropic Medications: A Consensus Statement From the American Society of Clinical Psychopharmacology Task Force.
Guidetti C, Chaikali S, Trivedi MH, Shelton RC, Iosifescu DV, Thase ME, Jha MK, Mathew SJ, DeBattista C, Dokucu ME, Brawman-Mintzer O, Ortiz JMH, Currier GW, McCall WV, Modirrousta M, Macaluso M, Bystritsky A, Vila-Rodriguez F, Nelson EB, Yeung AS, MacGregor LC, Carmody T, Fava M, Papakostas GI
Effect of augmentation with aripiprazole or augmentation with repetitive transcranial magnetic stimulation versus switching to the antidepressant venlafaxine extended release/duloxetine on cognition: A comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD). J Affect Disord. 2025 Dec 01; 390:119836.
Effect of augmentation with aripiprazole or augmentation with repetitive transcranial magnetic stimulation versus switching to the antidepressant venlafaxine extended release/duloxetine on cognition: A comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD).
Kapadia S, Zhang Z, Csoboth C, Patel M, Thase ME, Papakostas GI
Adjunctive brexpiprazole in patients with unresolved symptoms of depression on antidepressant treatment who are early in the disease course: post hoc analysis of randomized controlled trials. Int J Neuropsychopharmacol. 2025 Aug 01; 28(8).
Adjunctive brexpiprazole in patients with unresolved symptoms of depression on antidepressant treatment who are early in the disease course: post hoc analysis of randomized controlled trials.
Raskin J, Clayton AH, Kornstein SG, Papakostas GI, Prescott Y, Abernathy K, Hall J, Ackermann M, Wargin W, Rigdon G
A phase 2, multicenter, double-blind, randomized, placebo-controlled study of the safety and efficacy of forvisirvat (SP-624) in the treatment of adults with major depressive disorder. Curr Med Res Opin. 2025 Sep; 41(9):1723-1734.
A phase 2, multicenter, double-blind, randomized, placebo-controlled study of the safety and efficacy of forvisirvat (SP-624) in the treatment of adults with major depressive disorder.
Papakostas GI, Shelton RC, Zajecka JM, Bottiglieri T, Roffman J, Cassiello C, Stahl SM, Fava M
Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial. J Clin Psychiatry. 2014 Aug; 75(8):855-63.
Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial.
Jeon HJ, Fava M, Mischoulon D, Baer L, Clain A, Doorley J, DiPierro M, Cardoos A, Papakostas GI
Psychomotor symptoms and treatment outcomes of ziprasidone monotherapy in patients with major depressive disorder: a 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial. Int Clin Psychopharmacol. 2014 Nov; 29(6):332-8.
Psychomotor symptoms and treatment outcomes of ziprasidone monotherapy in patients with major depressive disorder: a 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial.
Mischoulon D, Price LH, Carpenter LL, Tyrka AR, Papakostas GI, Fava M
Dr. Mischoulon and colleagues reply. J Clin Psychiatry. 2014 Nov; 75(11):e1328-9.
Schatzberg AF, Blier P, Culpepper L, Jain R, Papakostas GI, Thase ME
An overview of vortioxetine. J Clin Psychiatry. 2014 Dec; 75(12):1411-8.
Updates and trends in the treatment of major depressive disorder. J Clin Psychiatry. 2014 Dec; 75(12):1419-21.
Updates and trends in the treatment of major depressive disorder.
Chen JA, Vijapura S, Papakostas GI, Parkin SR, Kim DJ, Cusin C, Baer L, Clain AJ, Fava M, Mischoulon D
Association between physician beliefs regarding assigned treatment and clinical response: re-analysis of data from the Hypericum Depression Trial Study Group. Asian J Psychiatr. 2015 Feb; 13:23-9.
Association between physician beliefs regarding assigned treatment and clinical response: re-analysis of data from the Hypericum Depression Trial Study Group.
Understanding and managing Cognition in the Depressed Patient. J Clin Psychiatry. 2015 04; 76(4):418-25.
Understanding and managing Cognition in the Depressed Patient.
The nature of placebo response in clinical studies of major depressive disorder. J Clin Psychiatry. 2015 Apr; 76(4):456-66.
The nature of placebo response in clinical studies of major depressive disorder.
Bilello JA, Thurmond LM, Smith KM, Pi B, Rubin R, Wright SM, Taub F, Henry ME, Shelton RC, Papakostas GI
MDDScore: confirmation of a blood test to aid in the diagnosis of major depressive disorder. J Clin Psychiatry. 2015 Feb; 76(2):e199-206.
MDDScore: confirmation of a blood test to aid in the diagnosis of major depressive disorder.
Heo JY, Jeon HJ, Fava M, Mischoulon D, Baer L, Clain A, Doorley J, Pisoni A, Papakostas GI
Efficacy of ziprasidone monotherapy in patients with anxious depression: a 12-week, randomized, double-blind, placebo-controlled, sequential-parallel comparison trial. J Psychiatr Res. 2015 Mar; 62:56-61.
Efficacy of ziprasidone monotherapy in patients with anxious depression: a 12-week, randomized, double-blind, placebo-controlled, sequential-parallel comparison trial.
Nierenberg AA, Østergaard SD, Iovieno N, Walker RS, Fava M, Papakostas GI
Predictors of placebo response in bipolar depression. Int Clin Psychopharmacol. 2015 Mar; 30(2):59-66.
Predictors of placebo response in bipolar depression.
Components of cognitive functioning and their measurement. J Clin Psychiatry. 2015 Jun; 76(6):e16.
Components of cognitive functioning and their measurement.
Sarris J, Price LH, Carpenter LL, Tyrka AR, Ng CH, Papakostas GI, Jaeger A, Fava M, Mischoulon D
Is S-Adenosyl Methionine (SAMe) for Depression Only Effective in Males? A Re-Analysis of Data from a Randomized Clinical Trial. Pharmacopsychiatry. 2015 Jul; 48(4-5):141-4.
Is S-Adenosyl Methionine (SAMe) for Depression Only Effective in Males? A Re-Analysis of Data from a Randomized Clinical Trial.
Yoo I, Woo JM, Lee SH, Fava M, Mischoulon D, Papakostas GI, Kim EJ, Chung S, Ha JH, Jeon HJ
Influence of anxiety symptoms on improvement of neurocognitive functions in patients with major depressive disorder: A 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study. J Affect Disord. 2015 Oct 01; 185:24-30.
Influence of anxiety symptoms on improvement of neurocognitive functions in patients with major depressive disorder: A 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study.
Antidepressants and their effect on cognition in major depressive disorder. J Clin Psychiatry. 2015 Aug; 76(8):e1046.
Antidepressants and their effect on cognition in major depressive disorder.
Papakostas GI, Shelton RC, Henry ME, Bilello JA
Reply to commentary by Rothschild: "A Blood Test for Depression?". J Clin Psychiatry. 2015 Aug; 76(8):e1038.
Reply to commentary by Rothschild: "A Blood Test for Depression?".
Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder. Mol Psychiatry. 2015 Oct; 20(10):1142-50.
Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder.
Shelton RC, Falola M, Li L, Zajecka J, Fava M, Papakostas GI
The pro-inflammatory profile of depressed patients is (partly) related to obesity. J Psychiatr Res. 2015 Nov; 70:91-7.
The pro-inflammatory profile of depressed patients is (partly) related to obesity.
Papakostas GI, Fava M, Baer L, Swee MB, Jaeger A, Bobo WV, Shelton RC
Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study. Am J Psychiatry. 2015 Dec; 172(12):1251-8.
Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study.
Shelton RC, Pencina MJ, Barrentine LW, Ruiz JA, Fava M, Zajecka JM, Papakostas GI
Association of obesity and inflammatory marker levels on treatment outcome: results from a double-blind, randomized study of adjunctive L-methylfolate calcium in patients with MDD who are inadequate responders to SSRIs. J Clin Psychiatry. 2015 Dec; 76(12):1635-41.
Association of obesity and inflammatory marker levels on treatment outcome: results from a double-blind, randomized study of adjunctive L-methylfolate calcium in patients with MDD who are inadequate responders to SSRIs.
Identifying patients with depression who require a change in treatment and implementing that change. J Clin Psychiatry. 2016 Feb; 77 Suppl 1:16-21.
Identifying patients with depression who require a change in treatment and implementing that change.
Iovieno N, Nierenberg AA, Parkin SR, Hyung Kim DJ, Walker RS, Fava M, Papakostas GI
Relationship between placebo response rate and clinical trial outcome in bipolar depression. J Psychiatr Res. 2016 Mar; 74:38-44.
Relationship between placebo response rate and clinical trial outcome in bipolar depression.
Zajecka JM, Fava M, Shelton RC, Barrentine LW, Young P, Papakostas GI
Long-term efficacy, safety, and tolerability of L-methylfolate calcium 15 mg as adjunctive therapy with selective serotonin reuptake inhibitors: a 12-month, open-label study following a placebo-controlled acute study. J Clin Psychiatry. 2016 May; 77(5):654-60.
Long-term efficacy, safety, and tolerability of L-methylfolate calcium 15 mg as adjunctive therapy with selective serotonin reuptake inhibitors: a 12-month, open-label study following a placebo-controlled acute study.
Papakostas GI, Martinson MA, Fava M, Iovieno N
Demographic variables, design characteristics, and effect sizes of randomized, placebo-controlled, monotherapy trials of major depressive disorder and bipolar depression. J Clin Psychiatry. 2016 May; 77(5):e619-24.
Demographic variables, design characteristics, and effect sizes of randomized, placebo-controlled, monotherapy trials of major depressive disorder and bipolar depression.
Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses. Am J Psychiatry. 2016 Jun 01; 173(6):575-87.
Baek JH, Kim HJ, Fava M, Mischoulon D, Papakostas GI, Nierenberg A, Heo JY, Jeon HJ
Reduced Venous Blood Basophil Count and Anxious Depression in Patients with Major Depressive Disorder. Psychiatry Investig. 2016 May; 13(3):321-6.
Reduced Venous Blood Basophil Count and Anxious Depression in Patients with Major Depressive Disorder.
Myung W, Han CE, Fava M, Mischoulon D, Papakostas GI, Heo JY, Kim KW, Kim ST, Kim DJ, Kim DK, Seo SW, Seong JK, Jeon HJ
Reduced frontal-subcortical white matter connectivity in association with suicidal ideation in major depressive disorder. Transl Psychiatry. 2016 06 07; 6(6):e835.
Reduced frontal-subcortical white matter connectivity in association with suicidal ideation in major depressive disorder.
Identifying Patients Who Need a Change in Depression Treatment and Implementing That Change. J Clin Psychiatry. 2016 08; 77(8):e1009.
Identifying Patients Who Need a Change in Depression Treatment and Implementing That Change.
S-Adenosyl Methionine(SAMe)Augmentation of SSRIs in MDD
1/2-Ziprasidone Augmentation of SSRIs for Treatment-Resistant Depression (TRD)
Trivedi MH, Bandelow B, Demyttenaere K, Papakostas GI, Papakosts GI, Szamosi J, Earley W, Eriksson H
Evaluation of the effects of extended release quetiapine fumarate monotherapy on sleep disturbance in patients with major depressive disorder: a pooled analysis of four randomized acute studies. Int J Neuropsychopharmacol. 2013 Sep; 16(8):1733-44.
Evaluation of the effects of extended release quetiapine fumarate monotherapy on sleep disturbance in patients with major depressive disorder: a pooled analysis of four randomized acute studies.
Ionescu DF, Shelton RC, Baer L, Meade KH, Swee MB, Fava M, Papakostas GI
Ziprasidone augmentation for anxious depression. Int Clin Psychopharmacol. 2016 11; 31(6):341-6.
Ziprasidone augmentation for anxious depression.
Mischoulon D, Shelton RC, Baer L, Bobo WV, Curren L, Fava M, Papakostas GI
Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Cardiac, Endocrine, Metabolic, and Motoric Effects in a Randomized, Double-Blind, Placebo-Controlled Study. J Clin Psychiatry. 2017 04; 78(4):449-455.
Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Cardiac, Endocrine, Metabolic, and Motoric Effects in a Randomized, Double-Blind, Placebo-Controlled Study.
Current Trends in Identifying Rapidly Acting Treatments for Depression. Curr Behav Neurosci Rep. 2016 Jun; 3(2):185-191.
Current Trends in Identifying Rapidly Acting Treatments for Depression.
Heo JY, Kim K, Fava M, Mischoulon D, Papakostas GI, Kim MJ, Kim DJ, Chang KJ, Oh Y, Yu BH, Jeon HJ
Effects of smartphone use with and without blue light at night in healthy adults: A randomized, double-blind, cross-over, placebo-controlled comparison. J Psychiatr Res. 2017 04; 87:61-70.
Effects of smartphone use with and without blue light at night in healthy adults: A randomized, double-blind, cross-over, placebo-controlled comparison.
Papakostas GI, Petersen TJ, Green C, Iosifescu DV, Yeung AS, Nierenberg AA, Fava M, Posternak MA
A description of next-step switching versus augmentation practices for outpatients with treatment-resistant major depressive disorder enrolled in an academic specialty clinic. Ann Clin Psychiatry. 2005 Jul-Sep; 17(3):161-5.
A description of next-step switching versus augmentation practices for outpatients with treatment-resistant major depressive disorder enrolled in an academic specialty clinic.
Papakostas GI, Petersen TJ, Perlis RH, Judy AE, Burns AM, Alpert JE, Birnbaum RJ, Fava M
A survey of antidepressant prescribing practices in major depression with comorbid attention-deficit hyperactivity disorder. J Clin Psychopharmacol. 2006 Apr; 26(2):216-8.
A survey of antidepressant prescribing practices in major depression with comorbid attention-deficit hyperactivity disorder.
Papakostas GI, Petersen T, Denninger J, Sonawalla SB, Mahal Y, Alpert JE, Nierenberg AA, Fava M
Somatic symptoms in treatment-resistant depression. Psychiatry Res. 2003 May 01; 118(1):39-45.
Somatic symptoms in treatment-resistant depression.
Papakostas GI, Petersen T, Sonawalla SB, Merens W, Iosifescu DV, Alpert JE, Fava M, Nierenberg AA
Serum cholesterol in treatment-resistant depression. Neuropsychobiology. 2003; 47(3):146-51.
Serum cholesterol in treatment-resistant depression.
Papakostas YG, Eftychiadis A, Papakostas GI, Christodoulou GN
A historical inquiry into the appropriateness of the term "panic disorder". Hist Psychiatry. 2003 Jun; 14(54 Pt 2):195-204.
A historical inquiry into the appropriateness of the term "panic disorder".
Reply to Fleisch et al. Letter. Am J Psychiatry. 2010 Dec; 167(12):1533.
Iosifescu DV, Renshaw PF, Lyoo IK, Lee HK, Perlis RH, Papakostas GI, Nierenberg AA, Fava M
The British journal of psychiatry : the journal of mental science
Brain white-matter hyperintensities and treatment outcome in major depressive disorder. Br J Psychiatry. 2006 Feb; 188:180-5.
Brain white-matter hyperintensities and treatment outcome in major depressive disorder.
Peterson TJ, Feldman G, Harley R, Fresco DM, Graves L, Holmes A, Bogdan R, Papakostas GI, Bohn L, Lury RA, Fava M, Segal ZV
Journal of consulting and clinical psychology
Extreme response style in recurrent and chronically depressed patients: change with antidepressant administration and stability during continuation treatment. J Consult Clin Psychol. 2007 Feb; 75(1):145-53.
Extreme response style in recurrent and chronically depressed patients: change with antidepressant administration and stability during continuation treatment.
Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder. World J Biol Psychiatry. 2007 Jul 13; 1-8.
Papakostas GI, Montgomery SA, Thase ME, Katz JR, Krishen A, Tucker VL
Comparing the rapidity of response during treatment of major depressive disorder with bupropion and the SSRIs: a pooled survival analysis of 7 double-blind, randomized clinical trials. J Clin Psychiatry. 2007 Dec; 68(12):1907-12.
Comparing the rapidity of response during treatment of major depressive disorder with bupropion and the SSRIs: a pooled survival analysis of 7 double-blind, randomized clinical trials.
Tolerability of modern antidepressants. J Clin Psychiatry. 2008; 69 Suppl E1:8-13.
Experimental medication treatment approaches for depression. Transl Psychiatry. 2017 03 21; 7(3):e1068.
Experimental medication treatment approaches for depression.
Nierenberg AA, Papakostas GI, Petersen T, Kelly KE, Iacoviello BM, Worthington JJ, Tedlow J, Alpert JE, Fava M
Nortriptyline for treatment-resistant depression. J Clin Psychiatry. 2003 Jan; 64(1):35-9.
Nortriptyline for treatment-resistant depression.
Environmental pollution (Barking, Essex : 1987)
Mercury in feathers of Squacco Heron (Ardeola ralloides) chicks in relation to age, hatching order, growth, and sampling dates. Environ Pollut. 2001; 111(1):107-15.
Mercury in feathers of Squacco Heron (Ardeola ralloides) chicks in relation to age, hatching order, growth, and sampling dates.
Iosifescu DV, Nierenberg AA, Alpert JE, Papakostas GI, Perlis RH, Sonawalla S, Fava M
Comorbid medical illness and relapse of major depressive disorder in the continuation phase of treatment. Psychosomatics. 2004 Sep-Oct; 45(5):419-25.
Comorbid medical illness and relapse of major depressive disorder in the continuation phase of treatment.
Dopaminergic-based pharmacotherapies for depression. Eur Neuropsychopharmacol. 2006 Aug; 16(6):391-402.
Dopaminergic-based pharmacotherapies for depression.
Petersen TJ, Alpert JE, Papakostas GI, Bernstein EM, Freed R, Smith MM, Fava M
Early-onset depression and the emotional and behavioral characteristics of offspring. Depress Anxiety. 2003; 18(2):104-8.
Early-onset depression and the emotional and behavioral characteristics of offspring.
Petersen T, Harley R, Papakostas GI, Montoya HD, Fava M, Alpert JE
Continuation cognitive-behavioural therapy maintains attributional style improvement in depressed patients responding acutely to fluoxetine. Psychol Med. 2004 Apr; 34(3):555-61.
Continuation cognitive-behavioural therapy maintains attributional style improvement in depressed patients responding acutely to fluoxetine.
Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry. 2004 Dec; 65(12):1607-18; quiz 1590, 1760-1.
Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism.
Iovieno N, Tedeschini E, Bentley KH, Evins AE, Papakostas GI
Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials. J Clin Psychiatry. 2011 Aug; 72(8):1144-51.
Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials.
Pedrelli P, Iovieno N, Vitali M, Tedeschini E, Bentley KH, Papakostas GI
Treatment of major depressive disorder and dysthymic disorder with antidepressants in patients with comorbid opiate use disorders enrolled in methadone maintenance therapy: a meta-analysis. J Clin Psychopharmacol. 2011 Oct; 31(5):582-6.
Treatment of major depressive disorder and dysthymic disorder with antidepressants in patients with comorbid opiate use disorders enrolled in methadone maintenance therapy: a meta-analysis.
Papakostas GI, Petersen T, Mischoulon D, Hughes ME, Spector AR, Alpert JE, Fava M, Nierenberg AA
Functioning and interpersonal relationships as predictors of response in treatment-resistant depression. Compr Psychiatry. 2003 Jan-Feb; 44(1):44-50.
Functioning and interpersonal relationships as predictors of response in treatment-resistant depression.
Farabaugh AH, Sonawalla SB, Fava M, Pedrelli P, Papakostas GI, Schwartz F, Mischoulon D
Differences in cognitive factors between "true drug" versus "placebo pattern" response to fluoxetine as defined by pattern analysis. Hum Psychopharmacol. 2006 Jun; 21(4):221-5.
Differences in cognitive factors between "true drug" versus "placebo pattern" response to fluoxetine as defined by pattern analysis.
Treatment-resistant depression. J Clin Psychiatry. 2006; 67 Suppl 6:16-22.
Iosifescu DV, Clementi-Craven N, Fraguas R, Papakostas GI, Petersen T, Alpert JE, Nierenberg AA, Fava M
Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder. Psychosom Med. 2005 Sep-Oct; 67(5):703-6.
Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder.
Sonawalla SB, Papakostas GI, Petersen TJ, Yeung AS, Smith MM, Sickinger AH, Gordon J, Israel JA, Tedlow JR, Lamon-Fava S, Fava M
Elevated cholesterol levels associated with nonresponse to fluoxetine treatment in major depressive disorder. Psychosomatics. 2002 Jul-Aug; 43(4):310-6.
Elevated cholesterol levels associated with nonresponse to fluoxetine treatment in major depressive disorder.
Papakostas GI, Petersen T, Pava J, Masson E, Worthington JJ, Alpert JE, Fava M, Nierenberg AA
The Journal of nervous and mental disease
Hopelessness and suicidal ideation in outpatients with treatment-resistant depression: prevalence and impact on treatment outcome. J Nerv Ment Dis. 2003 Jul; 191(7):444-9.
Hopelessness and suicidal ideation in outpatients with treatment-resistant depression: prevalence and impact on treatment outcome.
Papakostas GI, Petersen TJ, Farabaugh AH, Murakami JL, Pava JA, Alpert JE, Fava M, Nierenberg AA
Psychiatric comorbidity as a predictor of clinical response to nortriptyline in treatment-resistant major depressive disorder. J Clin Psychiatry. 2003 Nov; 64(11):1357-61.
Psychiatric comorbidity as a predictor of clinical response to nortriptyline in treatment-resistant major depressive disorder.
Iosifescu DV, Nierenberg AA, Mischoulon D, Perlis RH, Papakostas GI, Ryan JL, Alpert JE, Fava M
An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. J Clin Psychiatry. 2005 Aug; 66(8):1038-42.
An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder.
Levkovitz Y, Alpert JE, Brintz CE, Mischoulon D, Papakostas GI
Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. J Affect Disord. 2012 Feb; 136(3):1174-8.
Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder.
Papakostas GI, Iosifescu DV, Renshaw PF, Lyoo IK, Lee HK, Alpert JE, Nierenberg AA, Fava M
Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part II). Psychiatry Res. 2005 Dec 30; 140(3):301-7.
Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part II).
Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment switch from citalopram. Evid Based Ment Health. 2006 Nov; 9(4):100.
Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment switch from citalopram.
Nutt DJ, Baldwin DS, Clayton AH, Elgie R, Lecrubier Y, Montejo AL, Papakostas GI, Souery D, Trivedi MH, Tylee A
Consensus statement and research needs: the role of dopamine and norepinephrine in depression and antidepressant treatment. J Clin Psychiatry. 2006; 67 Suppl 6:46-9.
Consensus statement and research needs: the role of dopamine and norepinephrine in depression and antidepressant treatment.
Papakostas GI, Petersen T, Sklarsky KG, Nierenberg AA, Alpert JE, Fava M
Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. Psychiatry Res. 2007 Jan 15; 149(1-3):195-200.
Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder.
Papakostas GI, Petersen T, Hughes ME, Nierenberg AA, Alpert JE, Fava M
Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder. Psychiatry Res. 2004 May 30; 126(3):287-90.
Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder.
Dording CM, Sinicropi-Yao L, Papakostas G, Matthews JD, Nierenberg AA, Fava M, Mischoulon D
The response of psychotic-like symptoms to fluoxetine monotherapy in non-psychotic major depressive disorder. Nord J Psychiatry. 2009; 63(5):420-5.
The response of psychotic-like symptoms to fluoxetine monotherapy in non-psychotic major depressive disorder.
Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry. 2009; 70 Suppl 6:16-25.
Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder.
Papakostas GI, Cooper-Kazaz R, Appelhof BC, Posternak MA, Johnson DP, Klibanski A, Lerer B, Fava M
Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies. Int Clin Psychopharmacol. 2009 Jan; 24(1):19-25.
Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies.
Kornstein SG, Li D, Mao Y, Larsson S, Andersen HF, Papakostas GI
Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: integrative analysis of four double-blind, randomized clinical trials. CNS Spectr. 2009 Jun; 14(6):326-33.
Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: integrative analysis of four double-blind, randomized clinical trials.
Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach. J Clin Psychiatry. 2011 Jan; 72(1):98-113.
Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach.
Levkovitz Y, Tedeschini E, Papakostas GI
Efficacy of antidepressants for dysthymia: a meta-analysis of placebo-controlled randomized trials. J Clin Psychiatry. 2011 Apr; 72(4):509-14.
Efficacy of antidepressants for dysthymia: a meta-analysis of placebo-controlled randomized trials.
Limitations of contemporary antidepressants: tolerability. J Clin Psychiatry. 2007; 68 Suppl 10:11-7.
Limitations of contemporary antidepressants: tolerability.
Papakostas GI, Petersen T, Mahal Y, Mischoulon D, Nierenberg AA, Fava M
Quality of life assessments in major depressive disorder: a review of the literature. Gen Hosp Psychiatry. 2004 Jan-Feb; 26(1):13-7.
Quality of life assessments in major depressive disorder: a review of the literature.
Papakostas GI, Nutt DJ, Hallett LA, Tucker VL, Krishen A, Fava M
Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry. 2006 Dec 15; 60(12):1350-5.
Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors.
Papakostas GI, Kornstein SG, Clayton AH, Soares CN, Hallett LA, Krishen A, Tucker VL
Relative antidepressant efficacy of bupropion and the selective serotonin reuptake inhibitors in major depressive disorder: gender-age interactions. Int Clin Psychopharmacol. 2007 Jul; 22(4):226-9.
Relative antidepressant efficacy of bupropion and the selective serotonin reuptake inhibitors in major depressive disorder: gender-age interactions.
Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder. Dialogues Clin Neurosci. 2008; 10(4):439-51.
Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder.
Initial treatment approaches for patients with major depressive disorder. J Clin Psychiatry. 2009 Jun; 70(6):e18.
Initial treatment approaches for patients with major depressive disorder.
Miller KK, Perlis RH, Papakostas GI, Mischoulon D, Losifescu DV, Brick DJ, Fava M
Low-dose transdermal testosterone augmentation therapy improves depression severity in women. CNS Spectr. 2009 Dec; 14(12):688-94.
Low-dose transdermal testosterone augmentation therapy improves depression severity in women.
Papakostas GI, Petersen TJ, Kinrys G, Burns AM, Worthington JJ, Alpert JE, Fava M, Nierenberg AA
Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry. 2005 Oct; 66(10):1326-30.
Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder.
Papakostas GI, Hallett LA, Smith J, Tossani E, Mascarini A, Burns AM, Birnbaum RJ, Fava M, Alpert JE
A survey of five antidepressant properties influencing clinician's treatment choices in MDD. Neuropsychiatr Dis Treat. 2007 Feb; 3(1):169-72.
A survey of five antidepressant properties influencing clinician's treatment choices in MDD.
Pharmacologic and therapeutic strategies in treatment-resistant depression. Switching antidepressants vs. conventional augmentation strategies. CNS Spectr. 2009 Mar; 14(3 Suppl 4):11-4.
Pharmacologic and therapeutic strategies in treatment-resistant depression. Switching antidepressants vs. conventional augmentation strategies.
Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. Eur Psychiatry. 2012 Oct; 27(7):518-21.
Tedeschini E, Levkovitz Y, Iovieno N, Ameral VE, Nelson JC, Papakostas GI
Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials. J Clin Psychiatry. 2011 Dec; 72(12):1660-8.
Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials.
Iovieno N, Shelton RC, Petrie SR, Cusin C, Fava M, Papakostas GI
Efficacy of Ziprasidone Augmentation of Escitalopram for Cognitive Symptoms of Major Depressive Disorder. J Clin Psychiatry. 2018 Jan/Feb; 79(1).
Efficacy of Ziprasidone Augmentation of Escitalopram for Cognitive Symptoms of Major Depressive Disorder.
Fraguas R, Papakostas GI, Mischoulon D, Bottiglieri T, Alpert J, Fava M
Anger attacks in major depressive disorder and serum levels of homocysteine. Biol Psychiatry. 2006 Aug 01; 60(3):270-4.
Anger attacks in major depressive disorder and serum levels of homocysteine.
Papakostas GI, Petersen T, Mischoulon D, Hughes ME, Alpert JE, Nierenberg AA, Rosenbaum JF, Fava M
Serum cholesterol and serotonergic function in major depressive disorder. Psychiatry Res. 2003 May 30; 118(2):137-45.
Serum cholesterol and serotonergic function in major depressive disorder.
Papakostas GI, Iosifescu DV, Petersen T, Hamill SK, Alpert JE, Nierenberg AA, Rosenbaum JF, Fava M
Serum cholesterol in the continuation phase of pharmacotherapy with fluoxetine in remitted major depressive disorder. J Clin Psychopharmacol. 2004 Aug; 24(4):467-9.
Serum cholesterol in the continuation phase of pharmacotherapy with fluoxetine in remitted major depressive disorder.
Iosifescu DV, Papakostas GI, Lyoo IK, Lee HK, Renshaw PF, Alpert JE, Nierenberg A, Fava M
Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part I). Psychiatry Res. 2005 Dec 30; 140(3):291-9.
Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part I).
Denninger JW, Papakostas GI, Mahal Y, Merens W, Alpert JE, Nierenberg AA, Yeung A, Fava M
Somatic symptoms in outpatients with major depressive disorder treated with fluoxetine. Psychosomatics. 2006 Jul-Aug; 47(4):348-52.
Somatic symptoms in outpatients with major depressive disorder treated with fluoxetine.
The efficacy, tolerability, and safety of contemporary antidepressants. J Clin Psychiatry. 2010; 71 Suppl E1:e03.
The efficacy, tolerability, and safety of contemporary antidepressants.
Nutt DJ, Davidson JR, Gelenberg AJ, Higuchi T, Kanba S, Karamustafalioglu O, Papakostas GI, Sakamoto K, Terao T, Zhang M
International consensus statement on major depressive disorder. J Clin Psychiatry. 2010; 71 Suppl E1:e08.
International consensus statement on major depressive disorder.
Farabaugh AH, Bitran S, Witte J, Alpert J, Chuzi S, Clain AJ, Baer L, Fava M, McGrath PJ, Dording C, Mischoulon D, Papakostas GI
Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome. Int Clin Psychopharmacol. 2010 Jul; 25(4):214-7.
Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome.
Farabaugh A, Sonawalla S, Johnson DP, Witte J, Papakostas GI, Goodness T, Clain A, Baer L, Mischoulon D, Fava M, Harley R
Early improvements in anxiety, depression, and anger/hostility symptoms and response to antidepressant treatment. Ann Clin Psychiatry. 2010 Aug; 22(3):166-71.
Early improvements in anxiety, depression, and anger/hostility symptoms and response to antidepressant treatment.
Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram. Eur Arch Psychiatry Clin Neurosci. 2011 Apr; 261(3):147-56.
Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram.
Kornbluh R, Papakostas GI, Petersen T, Neault NB, Nierenberg AA, Rosenbaum JF, Fava M
A survey of prescribing preferences in the treatment of refractory depression: recent trends. Psychopharmacol Bull. 2001; 35(3):150-6.
A survey of prescribing preferences in the treatment of refractory depression: recent trends.
Papakostas GI, Petersen TJ, Iosifescu DV, Summergrad P, Sklarsky KG, Alpert JE, Nierenberg AA, Fava M
Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorder. J Clin Psychiatry. 2004 Apr; 65(4):543-6.
Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorder.
Papakostas GI, Petersen T, Mischoulon D, Ryan JL, Nierenberg AA, Bottiglieri T, Rosenbaum JF, Alpert JE, Fava M
Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression. J Clin Psychiatry. 2004 Aug; 65(8):1090-5.
Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression.
Alpert JE, Papakostas G, Mischoulon D, Worthington JJ, Petersen T, Mahal Y, Burns A, Bottiglieri T, Nierenberg AA, Fava M
S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. J Clin Psychopharmacol. 2004 Dec; 24(6):661-4.
S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine.
Papakostas GI, Petersen TJ, Burns AM, Fava M
Adjunctive atomoxetine for residual fatigue in major depressive disorder. J Psychiatr Res. 2006 Jun; 40(4):370-3.
Adjunctive atomoxetine for residual fatigue in major depressive disorder.
Papakostas GI, Perlis RH, Scalia MJ, Petersen TJ, Fava M
A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. J Clin Psychopharmacol. 2006 Feb; 26(1):56-60.
A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder.
Papakostas GI, Perlis RH, Seifert C, Fava M
Antidepressant dose reduction and the risk of relapse in major depressive disorder. Psychother Psychosom. 2007; 76(5):266-70.
Antidepressant dose reduction and the risk of relapse in major depressive disorder.
Papakostas GI, Petersen T, Denninger JW, Montoya HD, Nierenberg AA, Alpert JE, Fava M
Treatment-related adverse events and outcome in a clinical trial of fluoxetine for major depressive disorder. Ann Clin Psychiatry. 2003 Sep-Dec; 15(3-4):187-92.
Treatment-related adverse events and outcome in a clinical trial of fluoxetine for major depressive disorder.
Fava M, Freeman MP, Flynn M, Hoeppner BB, Shelton R, Iosifescu DV, Murrough JW, Mischoulon D, Cusin C, Rapaport M, Dunlop BW, Trivedi MH, Jha M, Sanacora G, Hermes G, Papakostas GI
Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD). Brain Stimul. 2018 Jan - Feb; 11(1):75-84.
Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD).
A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2007 Jan; 17(1):32-6.
A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder.
A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Can J Psychiatry. 2006 Oct; 51(12):783-90.
A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder.
A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Eur Psychiatry. 2007 Oct; 22(7):444-7.
A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder.
Dording CM, Fisher L, Papakostas G, Farabaugh A, Sonawalla S, Fava M, Mischoulon D
A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of SSRI-induced sexual dysfunction. CNS Neurosci Ther. 2008; 14(3):182-91.
A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of SSRI-induced sexual dysfunction.
Papakostas GI, Ongür D, Iosifescu DV, Mischoulon D, Fava M
Cholesterol in mood and anxiety disorders: review of the literature and new hypotheses. Eur Neuropsychopharmacol. 2004 Mar; 14(2):135-42.
Cholesterol in mood and anxiety disorders: review of the literature and new hypotheses.
Petersen T, Iosifescu DV, Papakostas GI, Shear DL, Fava M
Clinical characteristics of depressed patients with comorbid diabetes mellitus. Int Clin Psychopharmacol. 2006 Jan; 21(1):43-7.
Clinical characteristics of depressed patients with comorbid diabetes mellitus.
Simon NM, McNamara K, Chow CW, Maser RS, Papakostas GI, Pollack MH, Nierenberg AA, Fava M, Wong KK
A detailed examination of cytokine abnormalities in Major Depressive Disorder. Eur Neuropsychopharmacol. 2008 Mar; 18(3):230-3.
A detailed examination of cytokine abnormalities in Major Depressive Disorder.
Kim K, Kim SW, Myung W, Han CE, Fava M, Mischoulon D, Papakostas GI, Seo SW, Cho H, Seong JK, Jeon HJ
Reduced orbitofrontal-thalamic functional connectivity related to suicidal ideation in patients with major depressive disorder. Sci Rep. 2017 Nov 17; 7(1):15772.
Reduced orbitofrontal-thalamic functional connectivity related to suicidal ideation in patients with major depressive disorder.
Fava M, Papakostas GI, Petersen T, Mahal Y, Quitkin F, Stewart J, McGrath P
Switching to bupropion in fluoxetine-resistant major depressive disorder. Ann Clin Psychiatry. 2003 Mar; 15(1):17-22.
Switching to bupropion in fluoxetine-resistant major depressive disorder.
Efficacy of the sequential integration of psychotherapy and pharmacotherapy in major depressive disorder: a preliminary meta-analysis. Psychol Med. 2011 Feb; 41(2):321-31.
Efficacy of the sequential integration of psychotherapy and pharmacotherapy in major depressive disorder: a preliminary meta-analysis.
Papakostas GI, Shelton RC, Kinrys G, Henry ME, Bakow BR, Lipkin SH, Pi B, Thurmond L, Bilello JA
Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a pilot and replication study. Mol Psychiatry. 2013 Mar; 18(3):332-9.
Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a pilot and replication study.
Papakostas GI, Stahl SM, Krishen A, Seifert CA, Tucker VL, Goodale EP, Fava M
Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. J Clin Psychiatry. 2008 Aug; 69(8):1287-92.
Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies.
Papakostas GI, Petersen T, Homberger CH, Green CH, Smith J, Alpert JE, Fava M
Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder. Ann Clin Psychiatry. 2007 Jan-Mar; 19(1):5-8.
Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder.
Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC
Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry. 2007 Dec 01; 62(11):1217-27.
Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents.
Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M
S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry. 2010 Aug; 167(8):942-8.
S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial.
Evidence for S-adenosyl-L-methionine (SAM-e) for the treatment of major depressive disorder. J Clin Psychiatry. 2009; 70 Suppl 5:18-22.
Evidence for S-adenosyl-L-methionine (SAM-e) for the treatment of major depressive disorder.
Goodwin G, Fleischhacker W, Arango C, Baumann P, Davidson M, de Hert M, Falkai P, Kapur S, Leucht S, Licht R, Naber D, O'Keane V, Papakostas G, Vieta E, Zohar J
Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol. 2009 Jul; 19(7):520-32.
Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
Tedeschini E, Fava M, Goodness TM, Papakostas GI
Relationship between probability of receiving placebo and probability of prematurely discontinuing treatment in double-blind, randomized clinical trials for MDD: a meta-analysis. Eur Neuropsychopharmacol. 2010 Aug; 20(8):562-7.
Relationship between probability of receiving placebo and probability of prematurely discontinuing treatment in double-blind, randomized clinical trials for MDD: a meta-analysis.
Albanis TA, Hela D, Papakostas G, Goutner V
Concentration and bioaccumulation of organochlorine pesticide residues in herons and their prey in wetlands of Thermaikos Gulf, Macedonia, Greece. Sci Total Environ. 1996 Apr 05; 182(1-3):11-9.
Concentration and bioaccumulation of organochlorine pesticide residues in herons and their prey in wetlands of Thermaikos Gulf, Macedonia, Greece.
Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis. J Clin Psychiatry. 2012 Oct; 73(10):1300-6.
Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis.
Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry. 2008 Apr 01; 63(7):699-704.
Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches.
Mischoulon D, Best-Popescu C, Laposata M, Merens W, Murakami JL, Wu SL, Papakostas GI, Dording CM, Sonawalla SB, Nierenberg AA, Alpert JE, Fava M
A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder. Eur Neuropsychopharmacol. 2008 Sep; 18(9):639-45.
A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder.
Use of atypical antipsychotics for treatment-resistant major depressive disorder. Curr Psychiatry Rep. 2008 Dec; 10(6):481-6.
Use of atypical antipsychotics for treatment-resistant major depressive disorder.
Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009 Sep; 166(9):980-91.
Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials.
Iovieno N, Tedeschini E, Ameral VE, Rigatelli M, Papakostas GI
Antidepressants for major depressive disorder in patients with a co-morbid axis-III disorder: a meta-analysis of patient characteristics and placebo response rates in randomized controlled trials. Int Clin Psychopharmacol. 2011 Mar; 26(2):69-74.
Antidepressants for major depressive disorder in patients with a co-morbid axis-III disorder: a meta-analysis of patient characteristics and placebo response rates in randomized controlled trials.
Switching, combination, and augmentation strategies for major depressive disorder. Ann Clin Psychiatry. 2010 Nov; 22(4 Suppl 3):S9-14.
Switching, combination, and augmentation strategies for major depressive disorder.
Papakostas GI, Vitolo OV, Ishak WW, Rapaport MH, Zajecka JM, Kinrys G, Mischoulon D, Lipkin SH, Hails KA, Abrams J, Ward SG, Meisner A, Schoenfeld DA, Shelton RC, Winokur A, Okasha MS, Bari MA, Fava M
A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder. J Clin Psychiatry. 2012 Dec; 73(12):1541-7.
A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder.
S-adenosyl-methionine in depression: a comprehensive review of the literature. Curr Psychiatry Rep. 2003 Dec; 5(6):460-6.
S-adenosyl-methionine in depression: a comprehensive review of the literature.
Mischoulon D, Alpert JE, Arning E, Bottiglieri T, Fava M, Papakostas GI
Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive disorder. J Clin Psychiatry. 2012 Jun; 73(6):843-8.
Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive disorder.
Mischoulon D, Lamon-Fava S, Selhub J, Katz J, Papakostas GI, Iosifescu DV, Yeung AS, Dording CM, Farabaugh AH, Clain AJ, Baer L, Alpert JE, Nierenberg AA, Fava M
Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment. CNS Spectr. 2012 Jun; 17(2):76-86.
Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment.
Papakostas GI, Shelton RC, Zajecka JM, Etemad B, Rickels K, Clain A, Baer L, Dalton ED, Sacco GR, Schoenfeld D, Pencina M, Meisner A, Bottiglieri T, Nelson E, Mischoulon D, Alpert JE, Barbee JG, Zisook S, Fava M
L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry. 2012 Dec; 169(12):1267-74.
L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials.
Dean AC, Solomon G, Harden C, Papakostas G, Labar DR
Left hemispheric dominance of epileptiform discharges. Epilepsia. 1997 Apr; 38(4):503-5.
Left hemispheric dominance of epileptiform discharges.